Persistent symptoms, quality of life, and risk factors in long COVID: a cross-sectional study of hospitalized patients in Brazil

Oliveira, Jacqueline Ferreira; Ávila, Renata Eliane de; Oliveira, Neimy Ramos de; Sampaio, Natália da Cunha Severino; Gonçalves, Fabíola Araújo; Neto, Cirilo P. Fonseca; Milagres, Ana Carolina de Almeida; Gomes, Tatiane Cristina Caldeira; Pereira, Tássia Lopardi; Souza, Renan P.; Romero, Israel Molina

doi:10.1016/j.ijid.2022.07.063

Cited by 32 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 7 , 8 Third, many early reports have been cross-sectional, providing little information on how symptoms and other sequelae evolve. 9 , 10 , 11 …”

Section: Introductionmentioning

confidence: 99%

“…7,8 Third, many early reports have been cross-sectional, providing little information on how symptoms and other sequelae evolve. [9][10][11] In this article, we present the results of a prospective longitudinal study among adults hospitalized for COVID-19 in 44 hospitals across the US. By enrolling patients during hospitalization and conducting follow-up at 1, 3, and 6 months, we address the knowledge gaps noted above and provide critical data to help guide clinical care, public health, and scientific efforts.…”

Section: Introductionmentioning

confidence: 99%

“…Second, national studies using prospective enrollment of patients across diverse hospitals and regions are limited; increased geographic and temporal representation may reduce the analytical impact of regional health resource strain, surge conditions, and practice patterns on observed outcomes . Third, many early reports have been cross-sectional, providing little information on how symptoms and other sequelae evolve …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of Symptom, Disability, and Financial Trajectories in Patients Hospitalized for COVID-19 at 6 Months

et al. 2023

View full text Add to dashboard Cite

ImportanceIndividuals who survived COVID-19 often report persistent symptoms, disabilities, and financial consequences. However, national longitudinal estimates of symptom burden remain limited.ObjectiveTo measure the incidence and changes over time in symptoms, disability, and financial status after COVID-19–related hospitalization.Design, Setting, and ParticipantsA national US multicenter prospective cohort study with 1-, 3-, and 6-month postdischarge visits was conducted at 44 sites participating in the National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Network's Biology and Longitudinal Epidemiology: COVID-19 Observational (BLUE CORAL) study. Participants included hospitalized English- or Spanish-speaking adults without severe prehospitalization disabilities or cognitive impairment. Participants were enrolled between August 24, 2020, and July 20, 2021, with follow-up occurring through March 30, 2022.ExposureHospitalization for COVID-19 as identified with a positive SARS-CoV-2 molecular test.Main Outcomes and MeasuresNew or worsened cardiopulmonary symptoms, financial problems, functional impairments, perceived return to baseline health, and quality of life. Logistic regression was used to identify factors associated with new cardiopulmonary symptoms or financial problems at 6 months.ResultsA total of 825 adults (444 [54.0%] were male, and 379 [46.0%] were female) met eligibility criteria and completed at least 1 follow-up survey. Median age was 56 (IQR, 43-66) years; 253 (30.7%) participants were Hispanic, 145 (17.6%) were non-Hispanic Black, and 360 (43.6%) were non-Hispanic White. Symptoms, disabilities, and financial problems remained highly prevalent among hospitalization survivors at month 6. Rates increased between months 1 and 6 for cardiopulmonary symptoms (from 67.3% to 75.4%; P = .001) and fatigue (from 40.7% to 50.8%; P &lt; .001). Decreases were noted over the same interval for prevalent financial problems (from 66.1% to 56.4%; P &lt; .001) and functional limitations (from 55.3% to 47.3%; P = .004). Participants not reporting problems at month 1 often reported new symptoms (60.0%), financial problems (23.7%), disabilities (23.8%), or fatigue (41.4%) at month 6.Conclusions and RelevanceThe findings of this cohort study of people discharged after COVID-19 hospitalization suggest that recovery in symptoms, functional status, and fatigue was limited at 6 months, and some participants reported new problems 6 months after hospital discharge.

show abstract

“… 7 , 8 Third, many early reports have been cross-sectional, providing little information on how symptoms and other sequelae evolve. 9 , 10 , 11 …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of Symptom, Disability, and Financial Trajectories in Patients Hospitalized for COVID-19 at 6 Months

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Another limitation of this study was the short time horizon. When considering the process of recovering from COVID-19 and the potential for lingering symptoms, 18,19 the effect of CCP on quality of life beyond the 30-day period could not be assessed. Furthermore, the results from this study are also limited as only costs associated with hospital and ICU stay were included.…”

Section: Discussionmentioning

confidence: 99%

Quality of life and cost‐effectiveness of convalescent plasma compared to standard care for hospitalized COVID‐19 patients in the CONCOR‐1 trial

Tse,

Yan,

Liu

et al. 2024

Transfusion

View full text Add to dashboard Cite

BackgroundThe CONvalescent Plasma for Hospitalized Adults With COVID‐19 Respiratory Illness (CONCOR‐1) trial was a multicenter randomized controlled trial assessing convalescent plasma in hospitalized COVID‐19 patients. This study evaluates the cost‐effectiveness of convalescent plasma and its impact on quality‐of‐life to provide insight into its potential as an alternative treatment in resource‐constrained settings.MethodsIndividual patient data on health outcomes and resource utilization from the CONCOR‐1 trial were used to conduct the analysis from the Canadian public payer's perspective with a time horizon of 30 days post‐randomization. Baseline and 30‐day EQ‐5D‐5L were measured to calculate quality‐adjusted survival. All costs are presented in 2021 Canadian dollars. The base case assessed the EQ‐5D‐5L scores of hospitalized inpatients reporting at both timepoints, and a utility score of 0 was assigned for patients who died within 30 days. Costs for all patients enrolled were used. The sensitivity analysis utilizes EQ‐5D‐5L scores from the same population but only uses costs from this population.Results940 patients were randomized: 627 received CCP and 313 received standard care. The total costs were $28,716 (standard deviation, $25,380) and $24,258 ($22,939) for the convalescent plasma and standard care arms respectively. EQ‐5D‐5L scores were 0.61 in both arms (p = .85) at baseline. At 30 days, EQ‐5D‐5L scores were 0.63 and 0.64 for patients in the convalescent plasma and standard care arms, respectively (p = .46). The incremental cost was $4458 and the incremental quality‐adjusted life day was −0.078.DiscussionConvalescent plasma was less effective and more costly than standard care in treating hospitalized COVID‐19.

show abstract

“…Another Brazilian analysis evaluated the outcome of 439 patients with COVID-19 discharged from the hospital between 1 July 2020 and 31 March 2021. The main symptoms of long-COVID-19 were fatigue (63.1%), dyspnea (53.7%), arthralgia (56.1%), and depression/anxiety (55.1%) [ 42 ]. Although our study involved a unique cohort of outpatients with HTLV-1 and COVID-19 co-infection, we also found a high frequency of post-COVID-19 conditions (57.9%) despite the good evolution of all cases (most with one symptom), without hospitalization or death.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 among People Living with HTLV-1 Infection in Rio de Janeiro, Brazil

et al. 2023

View full text Add to dashboard Cite

The impact of coronavirus disease 2019 (COVID-19) on people living with human T-cell leukemia virus type 1 (HTLV-1) is unknown. The aim of this study is to evaluate the COVID-19 risk factors and outcomes of HTLV-1-infected individuals. A retrospective study of seropositive HTLV-1 outpatients seen during the COVID-19 pandemic period (2020–2022) was conducted in a Tertiary Hospital in Rio de Janeiro, Brazil. We compared the demographic and comorbidity/risk factors in patients with COVID-19 and non-COVID-19 diagnoses. In addition, the clinical features of COVID-19 and vaccination status were also investigated in 51 HTLV-1-infected individuals. The majority (88.2%) had COVID-19 comorbidity/risk factors. Seven cases were vaccinated against COVID-19. Overall, 19 out of 51 (37.3%) individuals were diagnosed with COVID-19. We found differences only in the frequency of anxiety in both groups: 57.9% in the COVID-19 group vs. 15.6% in the non-COVID-19 (p < 0.05) group. Thirteen out of nineteen (68%) of the COVID-19 cases progressed to mild/moderate illness, one remained asymptomatic, and 26.3% progressed to severe illness. All of the individuals recovered at home, but the majority (57.9%) developed post-COVID-19 symptoms: anosmia and ageusia (31.6%), worsening anxiety (15.8%), and a feeling of pain in the legs (15.8%). The patients with post-COVID-19 conditions were unvaccinated. Our findings show that HTLV-1 did not increase the risk of lethal COVID-19 and underline the importance of promoting mental health in HTLV-1-infected individuals.

show abstract

Persistent symptoms, quality of life, and risk factors in long COVID: a cross-sectional study of hospitalized patients in Brazil

Cited by 32 publications

References 23 publications

Assessment of Symptom, Disability, and Financial Trajectories in Patients Hospitalized for COVID-19 at 6 Months

Assessment of Symptom, Disability, and Financial Trajectories in Patients Hospitalized for COVID-19 at 6 Months

Quality of life and cost‐effectiveness of convalescent plasma compared to standard care for hospitalized COVID‐19 patients in the CONCOR‐1 trial

COVID-19 among People Living with HTLV-1 Infection in Rio de Janeiro, Brazil

Contact Info

Product

Resources

About